Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders.
Acetylcholinesterase
Chalcone
Monoamine oxidase
Piperazine
Journal
Environmental science and pollution research international
ISSN: 1614-7499
Titre abrégé: Environ Sci Pollut Res Int
Pays: Germany
ID NLM: 9441769
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
26
01
2021
accepted:
03
03
2021
pubmed:
21
3
2021
medline:
29
7
2021
entrez:
20
3
2021
Statut:
ppublish
Résumé
Eleven piperazine-containing 1,3-diphenylprop-2-en-1-one derivatives (PC1-PC11) were evaluated for their inhibitory activities against monoamine oxidases (MAOs), cholinesterases (ChEs), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) with a view toward developing new treatments for neurological disorders. Compounds PC10 and PC11 remarkably inhibited MAO-B with IC
Identifiants
pubmed: 33743158
doi: 10.1007/s11356-021-13320-y
pii: 10.1007/s11356-021-13320-y
pmc: PMC7980107
doi:
Substances chimiques
Chalcones
0
Cholinesterase Inhibitors
0
Monoamine Oxidase Inhibitors
0
Piperazine
1RTM4PAL0V
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38855-38866Subventions
Organisme : King saudi university
ID : RSP-2020/200
Organisme : Amrita Vishwa Vidyapeetham University
ID : K-PHAR-20-628
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Baek SC, Park MH, Ryu HW, Lee JP, Kang MG, Park D, Park CM, Oh SR, Kim H (2018a) Rhamnocitrin isolated from Prunus padus var. seoulensis: a potent and selective reversible inhibitor of human monoamine oxidase A. Bioorg Chem 28:317–325
Baek SC, Lee HW, Ryu HW, Kang MG, Park D, Kim SH, Cho ML, Oh SR, Kim H (2018b) Selective inhibition of monoamine oxidase A by hispidol. Bioorg Med Chem Lett 15:584–588
Bai P, Wang K, Zhang P, Shi J, Cheng X, Zhang Q, Zheng C, Cheng Y, Yang J, Lu X, Sang Z (2019) Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer’s disease. Eur J Med Chem 183:111737
Banks JL, Beard HS, Cao Y, Cho AE, Damm W, Farid R, Felts AK, Halgren TA, Mainz DT, Maple JR, Murphy R, Philipp DM, Repasky MP, Zhang LY, Berne BJ, Friesner RA, Gallicchio E, Levy RM (2005) Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem 26:1752–1780
Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3:205–214
Benny A, Thomas J (2019) Essential oil as treatment for Alzheimer’s disease: current and future perspectives. Planta Med 85:239–248
Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, Edmondson DE, Mattevi A (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 50:5848–5852
Brito AF, Moreira LKS, Menegatti R, Costa EA (2019) Piperazine derivatives with central pharmacological activity used as therapeutic tools. Fundam Clin Pharmacol 33:13–24
Carradori S, Silvestri R (2015) New frontiers in selective human MAO-B inhibitors. J Med Chem 58:6717–6732
Çeçen M, Oh JM, Özdemir Z, Büyüktuncel SE, Uysal M, Abdelgawad MA, Musa A, Gambacorta N, Nicolotti O, Mathew B, Kim H (2020) Design, synthesis, and biological evaluation of pyridazinones containing the (2-Fluorophenyl) Piperazine Moiety as Selective MAO-B Inhibitors. Molecules. 25:5371
Cheung J, Rudolph MJ, Burshteyn F, Cassidy MS, Gary EN, Love J, Franklin MC, Height JJ (2012) Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 55:10282–10286
Chimenti F, Fioravanti R, Bolasco A, Chimenti P, Secci D, Rossi F, Yáñez M, Orallo F, Ortuso F, Alcaro S (2009) Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem 52:2818–2824
Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717
Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749
Geldenhuys WJ, Youdim MB, Carroll RT, Van der Schyf CJ (2011) The emergence of designed multiple ligands for neurodegenerative disorders. Prog Neurobiol 94:347–359
Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discovery 10:449–461
Guglielmi P, Mathew B, Secci D, Carradori S (2020) Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors. Eur J Med Chem 205:112650
Jevtić II, Lai TH, Penjišević JZ, Dukić-Stefanović S, Andrić DB, Brust P, Kostić-Rajačić SV, Teodoro R (2020) Newly synthesized fluorinated cinnamylpiperazines possessing low in vitro MAO-B binding. Molecules 25:4941
Kaya B, Yurttaş L, Sağlik BN, Levent S, Özkay Y, Kaplancikli ZA (2017) Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors. J Enzyme Inhib Med Chem 32:193–202
Kumar B, Sheetal MAK, Kumar V (2018) Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors. Bioorg Chem 77:252–262
Lee JP, Kang MG, Lee JY, Oh JM, Baek SC, Leem HH, Park D, Cho ML, Kim H (2019) Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds. Bioorg Chem 89:103043
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795
Liu H, Fan H, Gao X, Huang X, Liu X, Liu L, Zhou C, Tang J, Wang Q, Liu W (2016) Design, synthesis and preliminary structure-activity relationship investigation of nitrogen-containing chalcone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors: a further study based on Flavokawain B Mannich base derivatives. J Enzyme Inhib Med Chem 31:580–589
Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234
Mangiatordi GF, Alberga D, Pisani L, Gadaleta D, Trisciuzzi D, Farina R, Carotti A, Lattanzi G, Catto M, Nicolotti O (2017) A rational approach to elucidate human monoamine oxidase molecular selectivity. Eur J Pharm Sci 101:90–99
Mathew B (2020) Privileged pharmacophore of FDA approved drugs in combination with chalcone framework: a new hope for Alzheimer’s treatment. Comb Chem High Throughput Screen 23:842–846
Mathew B, Haridas A, Uçar G, Baysal I, Adeniyi AA, Soliman ME, Joy M, Mathew GE, Lakshmanan B, Jayaprakash V (2016) Exploration of chlorinated thienyl chalcones: a new class of monoamine oxidase-B inhibitors. Int J Biol Macromol 91:680–695
Mathew B, Mathew GE, Petzer JP, Petzer A (2017) Structural exploration of synthetic chromones as selective MAO-B inhibitors: a mini review. Comb Chem High Throughput Screen 20:522–532
Mathew B, Baek SC, Grace Thomas Parambi D, Lee JP, Joy M, Annie Rilda PR, Randev RV, Nithyamol P, Vijayan V, Inasu ST, Mathew GE, Lohidakshan KK, Kumar Krishnan G, Kim H (2018) Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. MedChemComm 9:1871–1881
Mathew B, Baek SC, Thomas Parambi DG, Lee JP, Mathew GE, Jayanthi S, Vinod D, Rapheal C, Devikrishna V, Kondarath SS, Uddin MS, Kim H (2019a) Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: fluorinated chalcones of morpholine versus imidazole. Arch Pharm (Weinheim) 352:e1800309
Mathew B, Parambi DGT, Sivasankarapillai VS, Uddin MS, Suresh J, Mathew GE, Joy M, Marathakam A, Gupta SV (2019b) Perspective design of chalcones for the management of CNS disorders: a mini-review. CNS Neurol Disord Drug Targets 18:432–445
Mathew B, Carradori S, Guglielmi P, Uddin MS, Kim H (2020) New aspects of monoamine oxidase B inhibitors: the key role of halogens to open the golden door. Curr Med Chem 28:266–283. https://doi.org/10.2174/0929867327666200121165931
doi: 10.2174/0929867327666200121165931
Matos MJ, Vazquez-Rodriguez S, Uriarte E, Santana L (2015) Potential pharmacological uses of chalcones: a patent review (from June 2011 - 2014). Expert Opin Ther Pat 25:351–366
Modh RP, Kumar SP, Jasrai YT, Chikhalia KH (2013) Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors. Arch Pharm (Weinheim) 346:793–804
Morales-Camilo N, Salas CO, Sanhueza C, Espinosa-Bustos C, Sepúlveda-Boza S, Reyes-Parada M, Gonzalez-Nilo F, Caroli-Rezende M, Fierro A (2015) Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors. Chem Biol Drug Des 85:685–695
Moussa-Pacha NM, Abdin SM, Omar HA, Alniss H, Al-Tel TH (2019) BACE1 inhibitors: current status and future directions in treating Alzheimer’s disease. Med Res Rev 40:339–384
Oh JM, Rangarajan TM, Chaudhary R, Singh RP, Singh M, Singh RP, Tondo AR, Gambacorta N, Nicolotti O, Mathew B, Kim H (2020) Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors. Molecules 25:2356
Özdemir Z, Alagöz MA, Uslu H, Karakurt A, Erikci A, Ucar G, Uysal M (2020) Synthesis, molecular modelling and biological activity of some pyridazinone derivatives as selective human monoamine oxidase-B inhibitors. Pharmacol Rep 72:692–704
Pettersson F, Svensson P, Waters S, Waters N, Sonesson C (2012) Synthesis and evaluation of a set of para-substituted 4-phenylpiperidines and 4-phenylpiperazines as monoamine oxidase (MAO) inhibitors. J Med Chem 55:3242–3249
Rathi AK, Syed R, Shin HS, Patel RV (2016) Piperazine derivatives for therapeutic use: a patent review (2010-present). Expert Opin Ther Pat 26:777–797
Reeta, Baek SC, Lee JP, Rangarajan TM, Ayushee, Singh RP, Singh M, Mangiatordi GF, Nicolotti O, Kim H, Mathew B (2019) Ethyl acetohydroxamate incorporated chalcones: unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors against Alzheimer’s disease. CNS Neurol Disord Drug Targets 18:643–654
Robinson SJ, Petzer JP, Petzer A, Bergh JJ, Lourens AC (2013) Selected furanochalcones as inhibitors of monoamine oxidase. Bioorg Med Chem Lett 23:4985–4989
Sağlık BN, Cebeci O, Acar Çevik U, Osmaniye D, Levent S, Kaya Çavuşoğlu B, Ilgın S, Özkay Y, Kaplancıklı ZA (2020) Design, synthesis, in vitro and in silico studies of new thiazolylhydrazine-piperazine derivatives as selective MAO-A inhibitors. Molecules 25:E4342
Sahin Z, Ertas M, Bender C, Bülbül EF, Berk B, Biltekin SN, Yurttaş L, Demirayak Ş (2018) Thiazole-substituted benzoylpiperazine derivatives as acetylcholinesterase inhibitors. Drug Dev Res 79:406–425
Sasidharan R, Manju SL, Uçar G, Baysal I, Mathew B (2016) Identification of indole-based chalcones: discovery of a potent, selective, and reversible class of MAO-B inhibitors. Arch Pharm (Weinheim) 349:627–637
Sasidharan R, Baek SC, Sreedharannair Leelabaiamma M, Kim H, Mathew B (2018) Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors. Biomed Pharmacother 106:8–13
Sasidharan R, Eom BH, Heo JH, Park JE, Abdelgawad MA, Musa A, Gambacorta N, Nicolotti O, Manju SL, Mathew B, Kim H (2021) Morpholine based chalcones as dual acting monoamine oxidase-B and acetylcholinesterase inhibitors. Synthesis and biochemical investigations. J Enzyme Inhib Med Chem 36:188–197
Schrödinger Release 2020-4 (2020a) Glide, Schrödinger. LLC
Schrödinger Release 2020-4 (2020b) LigPrep, Schrödinger. LLC, New York
Schrödinger Release 2020-4: (2020c) Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2016; Impact, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger, LLC, New York, NY.
Shalaby R, Petzer JP, Petzer A, Ashraf UM, Atari E, Alasmari F, Kumarasamy S, Sari Y, Khalil A (2019) SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs. J Enzyme Inhib Med Chem 34:863–876
Son SY (2008) Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T (2008). Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A 105:5739–5744
Tipton KF (2018) 90 years of monoamine oxidase: some progress and some confusion. J Neural Transm (Vienna) 125:1519–1551
Tomar V, Bhattacharjee G, Kamaluddin KA (2007) Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2,5-dichlorothiophene moiety. Bioorg Med Chem Lett 17:5321–5324
Van Bulck M, Sierra-Magro A, Alarcon-Gil J, Perez-Castillo A, Morales-Garcia JA (2019) Novel approaches for the treatment of Alzheimer’s and Parkinson’s disease. Int J Mol Sci 20:719
Xiao G, Li Y, Qiang X, Xu R, Zheng Y, Cao Z, Luo L, Yang X, Sang Z, Su F, Deng Y (2017) Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease. Bioorg Med Chem 25:1030–1041
Zhang P, Xu S, Zhu Z, Xu J (2019) Multi-target design strategies for the improved treatment of Alzheimer’s disease. Eur J Med Chem 176:228–247
Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z (2017) Chalcone: a privileged structure in medicinal chemistry. Chem Rev 117:7762–7810